1 April 2023 false Taxfiler 2024.6 true 08799165business:PrivateLimitedCompanyLtd2023-04-012024-03-31 087991652023-03-31 087991652023-04-012024-03-31 08799165business:AuditExempt-NoAccountantsReport2023-04-012024-03-31 08799165business:AbridgedAccounts2023-04-012024-03-31 087991652024-03-31 08799165business:Director12023-04-012024-03-31 08799165business:RegisteredOffice2023-04-012024-03-31 087991652023-03-31 08799165core:WithinOneYear2024-03-31 08799165core:WithinOneYear2023-03-31 08799165core:ShareCapitalcore:PreviouslyStatedAmount2024-03-31 08799165core:ShareCapitalcore:PreviouslyStatedAmount2023-03-31 08799165core:SharePremiumcore:PreviouslyStatedAmount2024-03-31 08799165core:SharePremiumcore:PreviouslyStatedAmount2023-03-31 08799165core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2024-03-31 08799165core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2023-03-31 08799165core:PreviouslyStatedAmount2024-03-31 08799165core:PreviouslyStatedAmount2023-03-31 08799165business:SmallEntities2023-04-012024-03-31 08799165countries:EnglandWales2023-04-012024-03-31 087991652022-04-012023-03-31 iso4217:GBP xbrli:pure
Company Registration No. 08799165 (England and Wales)
OLIVE PHARMA LIMITED Unaudited accounts for the year ended 31 March 2024
OLIVE PHARMA LIMITED Unaudited accounts Contents
Page
- 2 -
OLIVE PHARMA LIMITED Company Information for the year ended 31 March 2024
Director
Atiq Saddique
Company Number
08799165 (England and Wales)
Registered Office
50 Highfield Lane Keighley BD21 2EH United Kingdom
- 3 -
OLIVE PHARMA LIMITED Statement of financial position as at 31 March 2024
2024 
2023 
Notes
£ 
£ 
Fixed assets
Intangible assets
250,232 
271,597 
Tangible assets
175,081 
198,852 
425,313 
470,449 
Current assets
Inventories
36,170 
83,670 
Debtors
907,386 
861,044 
Cash at bank and in hand
152,392 
214,156 
1,095,948 
1,158,870 
Creditors: amounts falling due within one year
(539,011)
(557,777)
Net current assets
556,937 
601,093 
Net assets
982,250 
1,071,542 
Capital and reserves
Called up share capital
100 
100 
Share premium
152,400 
152,400 
Profit and loss account
829,750 
919,042 
Shareholders' funds
982,250 
1,071,542 
For the year ending 31 March 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
The members have agreed to the preparation of abridged accounts for the year in accordance with Section 444(2A).
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board and authorised for issue on 24 December 2024 and were signed on its behalf by
Atiq Saddique Director Company Registration No. 08799165
- 4 -
OLIVE PHARMA LIMITED Notes to the Accounts for the year ended 31 March 2024
1
Statutory information
OLIVE PHARMA LIMITED is a private company, limited by shares, registered in England and Wales, registration number 08799165. The registered office is 50 Highfield Lane, Keighley, BD21 2EH, United Kingdom.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
Basis of preparation
The accounts have been prepared under the historical cost convention as modified by the revaluation of certain fixed assets.
Presentation currency
The accounts are presented in £ sterling.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Intangible fixed assets
Intangible fixed assets (including purchased goodwill and patents) are included at cost less accumulated amortisation.
Government grants
Government grants in relation to tangible fixed assets are credited to profit and loss account over the useful lives of the related assets, whereas those in relation to expenditure are credited when the expenditure is charged to profit and loss.
Going concern
At the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future.Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.
4
Intangible fixed assets
Total 
£ 
Cost
At 1 April 2023
335,692 
At 31 March 2024
335,692 
Amortisation
At 1 April 2023
64,095 
Charge for the year
21,365 
At 31 March 2024
85,460 
Net book value
At 31 March 2024
250,232 
At 31 March 2023
271,597 
- 5 -
OLIVE PHARMA LIMITED Notes to the Accounts for the year ended 31 March 2024
5
Tangible fixed assets
Total 
£ 
Cost or valuation
At 1 April 2023
322,739 
At 31 March 2024
322,739 
Depreciation
At 1 April 2023
123,887 
Charge for the year
23,771 
At 31 March 2024
147,658 
Net book value
At 31 March 2024
175,081 
At 31 March 2023
198,852 
6
Average number of employees
During the year the average number of employees was 28 (2023: 28).
- 6 -